Cite
MLA Citation
Sophie Godet et al.. “Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).” American journal of hematology, vol. 93, no. 2, n.d., pp. E52–E54. http://access.bl.uk/ark:/81055/vdc_100055537471.0x00004b